Q-omics provides the consensus-scored RTL5 profile across patient tissues and cancer cell-line models. RTL5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RTL5 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, RTL5 RNA expression shows 18,294 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, BLCA, and THYM as cancer lineages where RTL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTL5 survival associations across molecular data types. RTL5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTL5 RNA expression–survival associations across cancer types. High RTL5 expression shows favorable associations in LUAD, ACC, KIRC, PAAD, SKCM and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for RTL5 RNA expression.
This table summarizes RTL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RTL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTL5 shows lower tumor expression in BLCA, LUAD, COAD, LUSC, KIRC and UCEC. The BLCA box plot shows higher RTL5 RNA expression in normal versus tumor tissue (log2 FC = −3.181, t-test p < 0.001).
This table shows molecular features associated with RTL5 in patient tissues and cancer cell lines. In patient samples, RTL5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RTL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
